Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trialResearch in context

• Váldodahkkit: Ming-Ci Cai (Dahkki), Shu Cheng (Dahkki), Hong-Mei Jing (Dahkki), Yan Liu (Dahkki), Guo-Hui Cui (Dahkki), Ting Niu (Dahkki), Jian-Zhen Shen (Dahkki), Liang Huang (Dahkki), Xin Wang (Dahkki), Yao-Hui Huang (Dahkki), Li Wang (Dahkki), Peng-Peng Xu (Dahkki), Wei-Li Zhao (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2024-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Summary: Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with dismal outcomes. We conducted an open-label, phase 2 nonrandomised, externally controlled study to evaluate the efficacy and safety of targeted agents plus CHOP (cyclophosphamide, doxorubicin, vincristine, and pre...